[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634080":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":30,"locations":36,"responsibleParty":250,"collaborators":24,"id":252,"slug":253,"hasResults":254,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":24,"eligibilityCriteria":258,"healthyVolunteers":254,"sex":259,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":24,"studyType":265,"phases":266,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":39,"whyStopped":24,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":282},{"fullName":5,"class":6},"Crystalys Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dotinurad","EXPERIMENTAL","The Treatment Period will consist of 2 consecutive parts: a 24-week period where participants will take dotinurad (Treatment Period 1) followed by a 12-week period where participants will continue to take dotinurad (Treatment Period 2).",[13],"Drug: Dotinurad",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo + Placebo to Dotinuard","The Treatment Period will consist of 2 consecutive parts: a 24-week period where participants will take placebo (Treatment Period 1) followed by a 12-week treatment period where participants will take dotinurad (Treatment Period 2).",[13,18],"Other: Placebo",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Over-encapsulated tablets containing active drug substance administered orally.",[9,15],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"OTHER","Placebo","Capsules containing microcrystalline cellulose administered orally.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Clinical Trial Lead","CONTACT","(858) 356-4740","ClinicalTrials@crystalystx.com",[37,54,66,79,91,103,112,125,138,150,163,176,188,201,214,226,238],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Amicis Research Center","RECRUITING","Granada Hills","California","91344","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-118.52314,34.26472,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":24,"phoneExt":24,"email":24},"Pascal Dabel, MD",{"facility":55,"status":39,"city":56,"state":41,"zip":57,"country":43,"countryCode":44,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Cohen Medical Center","Thousand Oaks","91360",{"type":46,"coordinates":59},[60,61],-118.83759,34.17056,{"lat":61,"lon":60},[64],{"name":65,"role":33,"phone":24,"phoneExt":24,"email":24},"Shariar Cohen-Gadol, MD",{"facility":67,"status":39,"city":68,"state":69,"zip":70,"country":43,"countryCode":44,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Omega Research Group","DeBary","Florida","32713",{"type":46,"coordinates":72},[73,74],-81.30868,28.88305,{"lat":74,"lon":73},[77],{"name":78,"role":33,"phone":24,"phoneExt":24,"email":24},"Kwabena Ayesu, MD",{"facility":80,"status":39,"city":81,"state":69,"zip":82,"country":43,"countryCode":44,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Clinical Research of Central Florida","Lakeland","33805",{"type":46,"coordinates":84},[85,86],-81.9498,28.03947,{"lat":86,"lon":85},[89],{"name":90,"role":33,"phone":24,"phoneExt":24,"email":24},"Michael Gimness, MD",{"facility":92,"status":39,"city":93,"state":69,"zip":94,"country":43,"countryCode":44,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Panax Clinical Research","Miami","33014",{"type":46,"coordinates":96},[97,98],-80.19366,25.77427,{"lat":98,"lon":97},[101],{"name":102,"role":33,"phone":24,"phoneExt":24,"email":24},"Robert Perry, MD",{"facility":104,"status":39,"city":93,"state":69,"zip":105,"country":43,"countryCode":44,"cosmosGeoPoint":106,"geoPoint":108,"contacts":109},"Anchor Medical Research","33176",{"type":46,"coordinates":107},[97,98],{"lat":98,"lon":97},[110],{"name":111,"role":33,"phone":24,"phoneExt":24,"email":24},"Juvenal Martinez, MD",{"facility":113,"status":39,"city":114,"state":115,"zip":116,"country":43,"countryCode":44,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"MD Medical Research","Oxon Hill","Maryland","20745",{"type":46,"coordinates":118},[119,120],-76.9897,38.80345,{"lat":120,"lon":119},[123],{"name":124,"role":33,"phone":24,"phoneExt":24,"email":24},"Stephen Ong, MD",{"facility":126,"status":39,"city":127,"state":128,"zip":129,"country":43,"countryCode":44,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Clinical Research Institute of Michigan","Saint Clair Shores","Michigan","48081",{"type":46,"coordinates":131},[132,133],-82.88881,42.49698,{"lat":133,"lon":132},[136],{"name":137,"role":33,"phone":24,"phoneExt":24,"email":24},"Amar Majjhoo, MD",{"facility":139,"status":39,"city":140,"state":128,"zip":141,"country":43,"countryCode":44,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Revival Research Institute","Sterling Heights","48313",{"type":46,"coordinates":143},[144,145],-83.0302,42.58031,{"lat":145,"lon":144},[148],{"name":149,"role":33,"phone":24,"phoneExt":24,"email":24},"Syed Husain, MD",{"facility":151,"status":39,"city":152,"state":153,"zip":154,"country":43,"countryCode":44,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Las Vegas Clinical Trials","Las Vegas","Nevada","89030",{"type":46,"coordinates":156},[157,158],-115.13722,36.17497,{"lat":158,"lon":157},[161],{"name":162,"role":33,"phone":24,"phoneExt":24,"email":24},"Alton Walters, MD",{"facility":164,"status":39,"city":165,"state":166,"zip":167,"country":43,"countryCode":44,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Ellipsis Research Group","Brooklyn","New York","11215",{"type":46,"coordinates":169},[170,171],-73.94958,40.6501,{"lat":171,"lon":170},[174],{"name":175,"role":33,"phone":24,"phoneExt":24,"email":24},"Jorge Serje, MD",{"facility":177,"status":39,"city":178,"state":166,"zip":179,"country":43,"countryCode":44,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Drug Trials America","Hartsdale","10530",{"type":46,"coordinates":181},[182,183],-73.79819,41.01899,{"lat":183,"lon":182},[186],{"name":187,"role":33,"phone":24,"phoneExt":24,"email":24},"Michael Gerdis, MD",{"facility":189,"status":39,"city":190,"state":191,"zip":192,"country":43,"countryCode":44,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Shelby Clinical Research","Shelby","North Carolina","28150",{"type":46,"coordinates":194},[195,196],-81.53565,35.29235,{"lat":196,"lon":195},[199],{"name":200,"role":33,"phone":24,"phoneExt":24,"email":24},"Christian Martin, MD",{"facility":202,"status":39,"city":203,"state":204,"zip":205,"country":43,"countryCode":44,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"Zenos Clinical Research","Dallas","Texas","75230",{"type":46,"coordinates":207},[208,209],-96.80667,32.78306,{"lat":209,"lon":208},[212],{"name":213,"role":33,"phone":24,"phoneExt":24,"email":24},"Bachar Elsaadi, MD",{"facility":215,"status":39,"city":216,"state":204,"zip":217,"country":43,"countryCode":44,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"Epic Medical Research","DeSoto","75115",{"type":46,"coordinates":219},[220,221],-96.85695,32.58986,{"lat":221,"lon":220},[224],{"name":225,"role":33,"phone":24,"phoneExt":24,"email":24},"Haresh Boghara, MD",{"facility":227,"status":39,"city":228,"state":204,"zip":229,"country":43,"countryCode":44,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"Pioneer Research Solutions","Houston","77479",{"type":46,"coordinates":231},[232,233],-95.36327,29.76328,{"lat":233,"lon":232},[236],{"name":237,"role":33,"phone":24,"phoneExt":24,"email":24},"Francisco Velazquez, MD",{"facility":239,"status":39,"city":240,"state":204,"zip":241,"country":43,"countryCode":44,"cosmosGeoPoint":242,"geoPoint":246,"contacts":247},"DM Clinical Research","Tomball","77375",{"type":46,"coordinates":243},[244,245],-95.61605,30.09716,{"lat":245,"lon":244},[248],{"name":249,"role":33,"phone":24,"phoneExt":24,"email":24},"Shaikh Ali, MD",{"type":251,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100634080","phase-2-a-phase-2-trial-of-dotinurad-in-xanthine-oxidase-inhibitor-xoi-intoleranturicase-failure-gout-participants-100634080",false,"NCT07535034","A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant\u002FUricase Failure Gout Participants","A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad in Adult Participants With Gout Who Are Intolerant to Xanthine Oxidase Inhibitors or Failed Uricase Treatment","Inclusion Criteria:\n\n1. Between 18 and 75 years of age (inclusive) at the time of signing informed consent.\n2. Diagnosis of gout based on 2015 American College of Rheumatology (ACR)-European Union League Against Rheumatism (EULAR) criteria for at least 1 year and has at least 1 of the following:\n\n   * History (either by medical record or participant interview) of intolerance or a contraindication to either allopurinol or febuxostat.\n   * Failed uricase treatment (eg, an sUA level \\>6.0 mg\u002FdL at least 2 weeks after last infusion; intolerant or contraindicated to uricase treatment).\n3. sUA level \\>6.0 and \\\u003C10.5 mg\u002FdL at both Screening Visit 1 (Day -28 Visit) and Screening Visit 2 (Day -7 Visit).\n4. Female participants of childbearing potential must have a negative serum pregnancy test at Screening Visit 1 (Day -28 Visit), a negative urine pregnancy test on Day 1, and must not be breastfeeding.\n5. Fertile male participants and female participants of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use acceptable contraception from the time of signing informed consent through 30 days after the last dose of trial drug.\n\nExclusion Criteria:\n\n1. History of or presence of kidney stones within 1 year prior to Screening.\n2. History of or presence of malignancy in the last 5 years other than treated cutaneous basal or squamous cell carcinoma.\n3. Known or suspected history of drug abuse, a positive drug test at Screening Visit 1, or a recent history of alcohol abuse.\n4. Known history of or positive results for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) during Screening.\n5. Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, may compromise participant safety or trial compliance or may confound interpretation of trial results.","ALL","18 Years","75 Years",{"count":263,"type":264},90,"ESTIMATED","INTERVENTIONAL",[267],"PHASE2","The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.",[270],"Gout",[9,272],"Xanthine Oxidase Inhibitors","2026-06-08",{"date":275,"type":276},"2026-06-10","ACTUAL",{"date":278,"type":276},"2026-05-08",{"date":280,"type":264},"2027-08",{"name":5,"class":6},17]